Compile Data Set for Download or QSAR
Report error Found 465 Enz. Inhib. hit(s) with all data for entry = 911
TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298092(US10118930, Example 302 | 3-[3-(2-tert-butoxyethyl...)
Affinity DataIC50: 6nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298254(US10118930, Example 452 | 3-(2-methylbutanoyl)-7-(...)
Affinity DataIC50: 8nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298255(US10118930, Example 453 | 3-(cyclopropylcarbonyl)-...)
Affinity DataIC50: 8nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298041(US10118930, Example 253 | 3-(2-methyl-1,3-thiazol-...)
Affinity DataIC50: 8.20nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297950(US10118930, Example 166 | 7-(piperidin-4-yl)-3-{5-...)
Affinity DataIC50: 8.70nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298115(US10118930, Example 327 | 7-(piperidin-4-yl)-3-(pi...)
Affinity DataIC50: 9nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298123(US10118930, Example 335 | 3-(4-cyclohexyl-1,3-thia...)
Affinity DataIC50: 9nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298009(US10118930, Example 224 | 3-[3-(4-fluorobenzyl)-1,...)
Affinity DataIC50: 9.70nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298073(US10118930, Example 283 | 3-[5-(2-phenylethyl)-1,3...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298184(US10118930, Example 387 | Rel-3-{5-[(1R,2S)-2-meth...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298237(US10118930, Example 437 | 3-[3-(2-methoxyphenyl)-1...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298246(US10118930, Example 446 | 3-[3-(4-hydroxybenzyl)-1...)
Affinity DataIC50: 10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297791(US10118930, Example 16 | Ethyl 5-oxo-7-(piperidin-...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297845(US10118930, Example 68 | 5-[5-Oxo-7-(piperidin-4-y...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298063(US10118930, Example 274 | 3-[5-(3-chlorobenzyl)-1,...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298096(US10118930, Example 306 | 2-methyl-3-[3-(4-methylp...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298098(US10118930, Example 308 | 3-(4-ethyl-1,3-thiazol-2...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298127(US10118930, Example 338 | 3-(5-tert-butyl-1,3,4-ox...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298161(US10118930, Example 364 | Cyclobutyl 2-methyl-5-ox...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298170(US10118930, Example 373 | 7-(piperidin-4-yl)-3-(1,...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298253(US10118930, Example 451 | 3-(cyclopentylcarbonyl)-...)
Affinity DataIC50: 11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297809(US10118930, Example 34 | 7-(Piperidin-4-yl)-3-(3-p...)
Affinity DataIC50: 12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297842(US10118930, Example 65 | (−)-trans-7-(2-Meth...)
Affinity DataIC50: 12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297850(US10118930, Example 73 | 3-(Phenylsulfonyl)-7-(pip...)
Affinity DataIC50: 12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298037(US10118930, Example 249 | 3-{5-[4-methyl-2-(triflu...)
Affinity DataIC50: 12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298114(US10118930, Example 326 | 3-[(3,3-difluoroazetidin...)
Affinity DataIC50: 12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298238(US10118930, Example 438 | 3-[3-(2-fluorophenyl)-1,...)
Affinity DataIC50: 12nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297797(US10118930, Example 22 | N-Benzyl-5-oxo-7-(piperid...)
Affinity DataIC50: 13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297808(US10118930, Example 33 | 3-(3-Isopropyl-1,2,4-oxad...)
Affinity DataIC50: 13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297824(US10118930, Example 47 | 4-[5-Oxo-7-(piperidin-4-y...)
Affinity DataIC50: 13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297837(US10118930, Example 60 | 3-(3-Methoxyphenyl)-7-(pi...)
Affinity DataIC50: 13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298061(US10118930, Example 272 | 3-(5-methyl-4-phenyl-1,3...)
Affinity DataIC50: 13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297796(US10118930, Example 21 | N-Isobutyl-5-oxo-7-(piper...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297798(US10118930, Example 23 | 3-(Morpholin-4-ylcarbonyl...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297815(US10118930, Example 40 | (−)-trans-3-Chloro-...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297825(US10118930, Example 48 | 3-(3-Chlorophenyl)-7-(pip...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297847(US10118930, Example 70 | 7-(Piperidin-4-yl)-3-[3-(...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297939(US10118930, Example 155 | 7-(piperidin-4-yl)-3-{3-...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298065(US10118930, Example 276 | 3-[5-(2-chlorobenzyl)-1,...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298154(US10118930, Example 357 | Methyl 5-oxo-7-(piperidi...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298177(US10118930, Example 380 | 3-(5-Cyclopropyl-1,2,4-o...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298182(US10118930, Example 385 | 3-(5-Cyclopentyl-1,2,4-o...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298247(US10118930, Example 447 | 3-[5-(3-fluoro-4-methoxy...)
Affinity DataIC50: 14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297793(US10118930, Example 18 | Benzyl 5-oxo-7-(piperidin...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297794(US10118930, Example 19 | N-Ethyl-5-oxo-7-(piperidi...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297807(US10118930, Example 32 | 3-(3-Methyl-1,2,4-oxadiaz...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297810(US10118930, Example 35 | 3-(3-Phenyl-1,2,4-oxadiaz...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297830(US10118930, Example 53 | 3-(4-Methoxyphenyl)-7-(pi...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM297836(US10118930, Example 59 | 7-(Piperidin-4-yl)-3-(2-t...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

TargetTissue-type plasminogen activator(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM298005(US10118930, Example 220 | 3-[5-(4-methylphenyl)-1,...)
Affinity DataIC50: 15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/11/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 465 total ) | Next | Last >>
Jump to: